Frontline treatment of multiple myeloma in elderly patients

Blood Reviews

Volumn 22, Issue 6, 2008, Pages 303-309

  Moreau, Philippe ^a   Hulin, Cyrille ^b   Facon, Thierry ^c  

^a HÔTEL DIEU   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Bortezomib; Elderly patients; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENOXAPARIN; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISOLONE; THALIDOMIDE;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELDERLY CARE; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INFECTION; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PYOGENIC INFECTION; RASH; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; PYRAZINES; SURVIVAL RATE; THALIDOMIDE;

EID: 54049131660     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.04.002     Document Type: Article

References (29)

1. Alexanian R., Haut A., Khan A.U., et al. Treatment for multiple myeloma. Combination chemotherapy with different dose regimens. JAMA 208 (1969) 1680-1685
2. Bataille R., and Harousseau J.L. Multiple myeloma. New Engl J Med 336 (1997) 1657-1664
3. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
4. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
5. Facon T., Mary J.Y., Pegourié B., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
6. Attal M., Harousseau J.L., Stoppa A.M., et al. N Engl J Med 335 (1996) 91-97
7. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
8. Palumbo A., Triolo S., Argentino C., et al. Dose-intensive melphalan with stem cell support (mel100) is superior to standard treatment in elderly myeloma patients. Blood 94 (1999) 1248-1253
9. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
10. Palumbo A., Bertola A., Musto P., et al. Oral melphalan, prednisone and thalidomide for newly diagnosed patients with myeloma. Cancer 104 (2005) 1428-1433
11. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
12. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM99-06): a randomised trial. Lancet 370 (2007) 1209-1218
13. Hulin C., Virion J., Leleu X., et al. Melphalan-prednisone-thalidomide (MPT) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 110 (2007) 31a [abstract 75]
14. Palumbo A., and Boccadoro M. A new standard of care for elderly patients with myeloma. Lancet 370 (2007) 1191-1192
15. Waage A., Gimsing P., Juliusson G., Turesson I., and Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. Blood 110 (2007) 32a
16. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 (2008) 414-423
17. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma : 10 years later. Blood 2008 Feb1 [Epub ahead of print].
18. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9 (2003) 1136-1144
19. Berenson J.R., Yang H.H., Sadler K., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24 (2006) 937-944
20. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 (2006) 2165-2172
21. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93 (2008) 560-565
22. San Miguel J.F., Schlag R., Khuageva N., et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 110 (2007) 31a [abstract 76]
23. Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
24. Rajkumar S.V., Blood E., Vesole D., Fonseca R., and Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
25. Rajkumar SV, Rosinol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008 Mar 24 [Epub ahead of print].
26. Ludwig H., Tothova E., Hajek R., et al. Thalidomide-dexamethasone vs melphalan-prednisone as first line treatment and thalidomide-Interferon maintenance therapy in elderly patients with multiple myeloma. Blood 110 (2007) 163a [abstract 529]
27. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
28. Lacy M., Gertz M., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
29. Rajkumar S.V., Jacobus S., Callander N., et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 110 (2007) 31a [abstract 74]